p63 expression in normal skin and usual cutaneous carcinomas. by Reis-Filho, J et al.
J Cutan Pathol 2002: 29: 517–523 Copyright C Blackwell Munksgaard 2002




p63 expression in normal skin and usual
cutaneous carcinomas
Background: p63 is a p53 homologue that is mapped to Jorge S. Reis-Filho1,2,
chromosome 3q27. This gene encodes six different isoforms, which Beatriz Torio3,
have either transactivating or dominant negative effects on p53- Andre´ Albergaria1 and
reporter genes. It has been described that in contrast to p53, p63 Fernando C. Schmitt1,4
seems not to be associated with tumor predisposition, as neither p63 1IPATIMUP, Institute of Molecular Pathology
knockout mouse models nor germline p63 mutations are related to and Immunology, University of Porto, Porto,
2School of Health Sciences, University ofan increased risk of tumorigenesis. It has been demonstrated that p63
Minho, Braga, 3Department of Pathology,is a reliable keratinocyte stem cell marker and that it is involved in the
Hospital Fernando da Fonseca, Amadora-Sintra,maintenance of the stem cell population. Scant data on p63 expression Lisbon, and 4Porto Medical Faculty, University
in normal skin, basal cell carcinomas (BCCs), keratoacanthomas and of Porto, Porto, Portugal
squamous cell carcinomas (SCCs) have been reported. We herein
evaluated p63 expression in 16 BCCs, one keratoacanthoma and 13
SCCs.
Methods: Immunohistochemistry according to the streptavidin-
biotin-peroxidase technique, using the antibody 4A4 raised against all
p63 isoforms, was performed. p63 expression was evaluated in
epidermal cells and skin appendages. Semi-quantitative evaluation
(–, π, ππ, πππ) of p63 expression in BCCs, keratoacanthoma and
SCCs was carried out. Only nuclear expression was considered as
specific.
Results: p63 was expressed in the nuclei of epidermal basal and
suprabasal cells, in the cells of the germinative hair matrix and the
external root sheath of hair follicles, in the basal cells of the sebaceous
gland and in the myoepithelial/basal cells of the sweat glands. All
terminally differentiated cells were negative for p63. All BCCs showed
ππ to πππ immunoreactivity. At variance, keratoacanthomas and
grade I and II SCCs showed variable p63 reactivity in a basal layer-
like distribution, whereas undifferentiated cells of grade III SCCs
showed ππ to πππ positivity. A grade IV spindle SCC showed π
immunoreactivity. The SCCs in situ showed remarkable expression of
p63 in all cell layers. Terminally differentiated squamous cells were
either negative or showed only focal immunoreactivity in the
carcinomas.
Conclusions: p63 is consistently expressed in the basal cells of
epidermis and cutaneous appendages, including the basal/
myoepithelial cells of sweat glands. Based on our findings, the balance
of probabilities favors that p63 might play a role in the pattern of
R. Roberto Frias, S/N, 4200 Porto, Portugaldifferentiation and in the oncogenesis of usual carcinomas of the skin.
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p63 is a recently characterized p53 homologue whose
gene is located on 3q27 and encodes six different iso-
forms: three with transactivating (TA) properties (TA-
p63a, TA-p63b, and TA-p63g), which are capable
of transactivating p53 target genes and also inducing
apoptosis, and three truncated dominant negative iso-
forms that lack the N-terminal domain (DN) necessary
for activation of p53-reporter genes (DN-p63a, DN -
p63b and DN -p63g).1–4
Based on p63-knockout mouse models2,3 and in vi-
tro studies,5,6 p63 seems to play a major role in ecto-
dermal development, in the maintenance of a basal
cell population of stratified epithelia, and also in the
terminal differentiation of stratified epithelia.2,3,5,6
Yang et al.2 and Mills et al.3 elegantly described that
p63-/-mice have severe cranio-facial defects, defec-
tive epidermal differentiation, as well as lack of hair
follicles, teeth, prostate, sebaceous, sweat, mammary,
lachrymal or salivary glands.1–3
Consistent p63 expression has been demonstrated in
normal epidermal and basal cells of hair follicles.1–7
According to Pellegrini et al.7 p63 is a reliable keratino-
cyte stem cell marker4,7 and may be used to identify
these cells in the skin.7 Several lines of evidence point
toward a major role of p63 in the regulation of expres-
sion markers associated with keratinocyte differen-
tiation in stratified squamous epithelia, such as keratins
5 and 14, loricrin, filaggrin, involucrin, and transgluta-
minase 1.1–3,5,6 Indeed, it seems that p63 may induce
expression of differential markers and that shortly after,
p63 levels are progressively reduced.5,6 These findings
are in accordance with previous observations describ-
ing a progressive reduction of p63 levels from basal to
suprabasal epidermal cells.1–6
Regardless of the huge amount of data concerning
p63 expression in several types of human neoplasms
using tissue microarray technology,8 only scant studies
of p63 expression in normal skin and usual primary
skin carcinomas5,8 have hitherto been performed on
routinely processed formalin-fixed paraffin-embedded
tissue sections. We herein describe p63 expression in
normal epidermis, cutaneous appendages, in situ
squamous cell carcinoma (isSCC), invasive squamous
cell carcinomas (ISCC), and basal cell carcinomas
(BCC). As DN-p63 isoforms may act as ‘oncogenes’
(may constitute an alternative mechanism to over-
come p53-driven cell cycle arrest and apoptosis)1–4
we also evaluated whether or not p63 overexpression
could be related to some of the morphologic traits
frequently associated with the aggressiveness of usual
cutaneous neoplasms, including growth pattern, de-
gree of desmoplasia, presence of vascular/lymphatic




Thirteen consecutive cases of squamous cell carci-
nomas, with and without an associated in situ compo-
nent, and 17 consecutive cases of basal cell carci-
nomas were retrospectively retrieved from the files of
the Department of Pathology, Hospital Fernando da
Fonseca, Lisbon, Portugal. The clinical pathologic
data was collected from the pathology reports. All
cases were independently reviewed by two of the
authors (JSRF, BT) and the diagnoses were recon-
firmed in all but two cases (one squamous cell carci-
noma was reclassified as a keratoacanthoma and one
‘metatypical’ carcinoma was reclassified as a squam-
ous cell carcinoma). Squamous cell carcinomas (SCC)
were graded according to Broders’ criteria9 and basal
cell carcinomas were classified according to Rippey’s
classification.10 All cases were also classified according
to the presence of an in situ component, growth pat-
tern (infiltrative vs. expansile), degree of desmoplasia,
presence of vascular/lymphatic invasion, and peri-
neural infiltration. Mitotic counting was reported as
the number of mitotic figures per 10 consecutive high
power magnification fields (HPF) in the most prolifer-
ative areas.
Immunohistochemical analysis
For all cases, a 4-mm histologic section was cut and
mounted on a silane-coated slide. Immunohistochem-
istry using the streptavidin-biotin-peroxidase tech-
nique with a monoclonal antibody raised against p63
(clone 4A4, dilution 1 :150, Neomarkers, Freemont,
CA, USA) was performed as described elsewhere.11
Heat-induced antigen retrieval using the Dako Anti-
gen Retrieval Solution (Dako, Glostrup, Denmark)
was previously performed in a wet bath for 20min in
all cases. Positive and negative controls were included
in each slide run. Only nuclear p63 expression was
accepted as specific.
The distribution of p63 expression in the normal
epidermis, sweat glands, sebaceous glands, hair fol-
licles, dermal mesenchymal cells, endothelial cells,
pericytes, erector muscles, nerve bundles, and adipo-
cytes was evaluated in normal skin adjacent to the
neoplasms. A semi-quantitative assessment of p63 ex-
pression was performed for in situ squamous cell carci-
nomas, invasive squamous cell carcinomas, and basal
cell carcinomas, according to the following criteria:
–, negative nuclear staining of neoplastic cells;π,
focal (5%) positivity of neoplastic cells;ππ, moder-
ate (5–50%) positivity of neoplastic cells; and πππ,
diffuse (50%) positivity of neoplastic cells. Owing
to the remarkable differential p63 expression in cells
showing basal cell-like/undifferentiated morphology
and terminally differentiation morphology in SCC
and BCC, p63 expression was separately semiquant-
ified in each cell type.
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Statistical analysis
Statistical analysis was performed using Statview soft-
ware (4.0, SAS Institute Inc., Cary, NC, USA). Statisti-
cal differences between p63 expression and histologic
type, histologic grade of SCCs, BCC types, presence of
vascular/lymphatic invasion, and the presence of peri-
neural infiltration were calculated using the Chi-square
test. Analysis of variance () with Yates’ correction
was used to compare p63 expression and mean values
for age and mitotic counting. A level of p0.05 was
considered significant.
Results
Clinical and pathologic data
The age of the patients ranged from 32 to 82years
(median age 62years for patients with SCC and 73.5
for patients with BCC). All patients were white. All
tumors affected sun-exposed skin.Table1 summarizes
the clinical pathologic data.
All squamous cell carcinomas showed variable
keratinization; according to Broders’ criteria9 three
were classified as grade I, five as grade II, four as
grade III, and one as grade IV. The latter was a bona
Table1. Summary of the pathologic clinical data of the cases
Biopsy Age Diagnosis Histologic Borders Desmoplasia Perineural Vascular invasion Mitotic
type/grade invasion
1 77 BCC Metatypical Infiltrative Intense Present Absent 24
2 66 BCC Metatypical Infiltrative Intense Absent Absent 34
3 75 BCC Metatypical Infiltrative Intense Absent Present 56
4 82 BCC Nodular Expansile Low Absent Absent 18
5 80 BCC Mixed Infiltrative Low Absent Absent 29
6 59 BCC Mixed Infiltrative Moderate Absent Absent 23
7 62 BCC Mixed Infiltrative Moderate Absent Present 31
8 72 BCC Nodular Expansile Low Absent Absent 42
9 70 BCC Nodular Expansile Moderate Absent Absent 10
10 75 BCC Nodular Expansile Low Absent Absent 19
11 80 BCC Micronodular Expansile Low Absent Absent 4
12 63 BCC Nodular Expansile Low Absent Absent 2
13 75 BCC Nodular Expansile Low Absent Absent 46
14 64 BCC Nodular Expansile Low Absent Absent 16
15 64 BCC Nodular Expansile Low Absent Absent 8
16 75 BCC Nodular Expansile Low Absent Absent ND*
17 76 Keratoacanthoma Expansile Low Absent Absent ND
18 75 SCC GI Expansile Moderate Absent Absent 26
19 67 SCC GI Infiltrative Moderate Absent Absent 30
20 54 SCC GI Infiltrative Intense Absent Absent 45
21 57 SCC GII Infiltrative Moderate Absent Present 54
22 66 SCC GII Infiltrative Moderate Present Present 13
23 42 SCC GII Infiltrative Moderate Present Absent 26
24 32 SCC GII Infiltrative Intense Absent Absent 33
25 74 SCC GII Infiltrative Moderate Absent Absent 13
26 55 SCC GIII Expansile Moderate Absent Absent 33
27 71 SCC GIII Infiltrative Moderate Absent Absent 19
28 59 SCC GIII Infiltrative Moderate Absent Present 181
29 62 SCC GIII Infiltrative Moderate Absent Present 74
30 67 SCC GIV/SCC Infiltrative Moderate Present Present 16
BCC, basal cell carcinoma; GI, grade I; GII, grade II; GIII, grade III; GIV, grade IV; HPF, high power fields; ND, not available; SCC, squamous cell
carcinoma.
*The biopsy did not have enough tissue to allow the evaluation of 10 high power magnification fields.
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fide example of spindle cell SCC,9 showing inter-
secting fascicles of variably pleomorphic spindle cells.
In seven cases, an associated in situ component was
depicted. Eleven cases showed infiltrative borders and
two exhibited a remarkably expansile growth pattern.
Eleven cases showed moderate desmoplasia and two
showed a prominent desmoplastic reaction. Vascular/
lymphatic invasion was observed in five cases and
perineural invasion was observed in three cases. Mi-
totic figures ranged from 13 to 181/10HPF, with a
mean of 43.3/10HPF and a median of 30/10HPF.
The case initially diagnosed as a grade I SCC
and reclassified as a keratoacanthoma showed the
typical morphologic features that characterize kera-
toacanthomas. Briefly, it was a symmetric lesion
with deeply situated bulbous lobules of squamous
cells showing variably atypical nuclei and a rather
remarkable eosinophilic glassy cytoplasm. There was
an abrupt transition between the lesion and the
adjacent epidermis which lacked atypical cells sug-
gestive of isSCC. Admixed with the squamous cell
lobules, there were scattered microabscesses.9 Sur-
rounding the lesion, a mixed inflammatory infiltrate
predominantly composed of lymphocytes and
eosinophils was depicted.
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Concerning BCCs, the histologic subtypes10 are
specified in Table1. Ten cases were of the nodular
histologic type (including four with an adenoid pat-
tern and four pigmented BCCs) and one showed a
micronodular pattern. In three cases there was a com-
plex admixture of two types of cells: 1) cells with dark-
ly stained nuclei and scant cytoplasm, indistinguish-
able from those observed in bona fide BCCs, 2) and
neoplastic cells showing a more vesicular and atypical
nuclei, with prominent nucleoli, and more abundant
eosinophilic cytoplasm. In all of these cases, neoplas-
tic cells were arranged in infiltrative cords with ill-
defined peripheral palisades, and were immersed in a
highly desmoplastic stroma, showing obvious stromal-
epithelial separation artifacts. In addition, the features
of squamous differentiation were unevenly observed,
but squamous pearls were not found.12 We preferred
to classify these cases as ‘metatypical carcinomas’, but
they could also be classified as basal cell carcinomas
with incomplete squamous differentiation, infiltrative
borders and prominent desmoplasia.10 Ten cases
showed expansile borders and six showed an infiltrat-
ive growth pattern. Ten cases showed low desmoplas-
tic stromal reactions; and moderate and intense de-
smoplasia were observed in three cases each. Vascu-
lar/lymphatic invasion was observed in two cases and
perineural infiltration in a further case. Mitotic figures
ranged from 2 to 56/10HPF, with a mean of 24.1/
10HPF and a median of 23.0/10HPF.
P63 expression
Normal skin
In normal skin, p63 was consistently expressed in the
nuclei of the epidermal basal cells(Fig. 1A), cells of the
germinative hair matrix and the external root sheath
of the hair follicles (Fig. 1B). No p63 staining was ob-
served in the cells of the Henle’s layer, Huxley’s layer,
cuticle, or in the perifollicular connective tissue
sheath. The nuclei of the sebaceous gland basal cells
were strongly stained by p63 (Fig. 1C) and an uneven
nuclear staining of the apocrine and eccrine sweat
glands’ basal/myoepithelial cells was depicted (Fig.
1D). No dermal mesenchymal cell, endothelial cell,
pericyte, smooth muscle cell, neural cell, or adipocyte
showed any immunoreactivity for p63.
Squamous cell carcinomas and keratoacanthoma
As previously reported,5,8,13,14 p63 expression in
squamous cell carcinomas showed a peculiar distri-
bution. In grade I lesions and in the keratoacantho-
ma, p63 stained the nuclei of cells arranged in a
basal-like pattern(Fig. 2A); the terminally differen-
tiated, keratinized squamous cells lacked any p63 im-
munoexpression. In grade II and grade III lesions,
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Fig. 1 p63 expression in normal skin. (A) Basal and suprabasal epi-
dermal cells with nuclei decorated by p63. (B) Hair follicle (anagen
growth phase): strong p63 expression in the nuclei of hair matrix
cells and cells of the external root sheath. (C) p63 expression in
basal cells of the sebaceous glands. (D) Sweat glands with p63-
positive cells in a basal cell distribution. (Streptavidin-biotin-peroxi-
dase/DAB). Original magnifications: A, 200¿; B, 100¿; C, 100
¿; D, 200¿.
Fig. 2 p63 expression in keratoacanthoma and squamous cell carci-
noma (SCC). (A) p63 expression in a keratoacanthoma showing a
basal cell layer-like pattern. (B) Grade III SCC with strong p63
immunoreactivity in undifferentiated cells and lack of p63 staining
in cells showing terminal squamous differentiation. Inset: p63 ex-
pression in a squamous pearl. (C) Spindle cell SCC. Inset: focal but
strong immunoreactivity for p63 in the nuclei of neoplastic cells.
(D) SCC in situ adjacent to invasive GIII SCC. Note the p63 over-
expression. (A, B, B inset, C inset and D: streptavidin-biotin-peroxi-
dase/DAB; C: H&E). Original magnifications: A, 40¿; B, 100¿?
B (inset), 400¿; C (inset), 200¿; D, 100¿.
the nuclei of undifferentiated squamous cells were
strongly decorated by p63 (Fig. 2B); conversely, a
gradual reduction of p63 was observed toward the
more differentiated cells. Only two cases showed focal
immunoreactivity for p63 in the differentiated squam-
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Table2. p63 expression in usual cutaneous carcinomas
Cases p63 in basal/undifferentiated cells p63 expression in differentiated squamous cells
ª π ππ πππ ª π ππ πππ
BCC 0 0 4 12 16 0 0 0
Solid 0 0 2 3 5 0 0 0
Micronodular 0 0 0 1 1 0 0 0
Mixed 0 0 2 5 7 0 0 0
Metatypical 0 0 0 3 1 2 0 0
Keratoacanthoma 0 1 0 0 0 0 0 0
SCC 0 5 3 5 11 1 1 0
GI 0 2 1 0 3 0 0 0
GII 0 2 1 2 3 1 1 0
GIII 0 0 1 3 4 0 0 0
GIV 0 1 0 0 1 0 0 0
–, Negative nuclear staining; π, focal positivity (5% of neoplastic cells); ππ, moderate positivity (5–50% of neoplastic cells); πππ, diffuse
immunoreactivity (50% of neoplastic cells).
BCC, basal cell carcinoma; GI, grade I; GII, grade II; GIII, grade III; GIV, grade IV; SCC, squamous cell carcinoma.
ous cells. In the spindle cell carcinoma, moderate/
focal immunoreactivity was seen (Fig. 2C).
Table2 summarizes the semiquantitative distri-
bution of p63 immunoreactive cells in SCCs. Briefly,
in the grade I tumors, two cases showed π and one
case showed ππ reactivity for p63; in the grade II
tumors, two cases showed πππ, two cases showed
π and one case showed π immunoreactivity for p63.
The grade III SCCs were diffusely positive for p63 in
all but one case, which showed ππ positivity. The
grade IV spindle cell carcinoma showed π (focal) im-
munoreactivity.
In the in situ component adjacent to the invasive
SCCs, p63 showed a rather peculiar distribution.
While in the normal epidermis, p63 was restricted to
basal and occasional suprabasal cells, in isSCC, p63
decorated almost all cell layers (Fig. 2D). Interestingly,
no other areas showed p63 expression in superficial
(granular and prickle) epidermal layers.
Basal cell carcinomas
All basal cell carcinomas with infiltrative borders
showed diffuse (πππ) positivity for p63(Fig. 3A) in-
Fig. 3 p63 expression in basal cell carcinomas (BCCs).(A)Infiltrative
BCC with strong p63 expression. (B) BCC with expansile borders
showing marked p63 immunoexpression. Inset: note that all cells,
including those in a palisade arrangement, are decorated by p63.
(Streptavidin-biotin-peroxidase/DAB). Original magnifications: A,
100¿; B, 100¿; (B) inset, 400¿.
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dependently of the other variables. Six and four BCC
cases with expansile growth patterns showed πππ
(Fig. 3B) and ππ immunoreactivity for p63, respec-
tively, regardless of their histologic subtype and de-
gree of desmoplastic stromal reaction. Interestingly, in
eight cases scattered terminally differentiated squam-
ous cells were observed. In two out of these cases,
focal nuclear immunoreactivity for p63 was also ob-
served.
Statistical analysis
There was a statistically significant more diffuse ex-
pression of p63 in the BCCs as compared to the SCCs
(pΩ0.025). No other statistically significant associ-
ation between p63 and other pathologic parameters,
including age, growth pattern, desmoplasia, vascular/
lymphatic invasion, perineural infiltration and mitotic
counting was observed.
Discussion
p63 is a p53 homologue that seems to play distinctive
roles in the physiology of skin. First, knockout mouse
models2,3 have demonstrated that p63 is fundamental
for the development of skin and cutaneous append-
ages.2,3 Histologic analysis of these mice revealed that
their skin lacked the structured stratification normally
observed;2,3 p63-/-late-stage embryos and newborns
only retain scattered patches of disorganized epithelial
cells along the epidermal surface.1–3 Interestingly, in
these mice, epidermal basal cells fail to express the
markers of squamous differentiation, such as keratin
5 and 14, loricrin, filaggrin, involucrin, and transglut-
aminase 1.1–3,6 Based on these findings, p63 seems to
be fundamental for the differentiation and specializa-
tion of epithelial cells forming stratified epithelia. In
addition, Parsa et al.5 and De Laurenzi et al.6 el-
egantly demonstrated that p63 expression is gradually
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reduced from the basal cells to the terminally differen-
tiated keratinocytes.5–7 These findings are in accord-
ance with what was observed in our study: strong p63
expression in basal cells and occasional suprabasal
cells and lack of p63 staining in superficial epidermal
layers.
Another role played by p63 involves the mainten-
ance of a basal/stem cell population in stratified epi-
thelia.1–4,7,15,16 The p63 gene encodes at least six pro-
teins: three with transactivating (TA) and three with
dominant negative (DN) effects on p53 reporter
genes.1–4 As p53 plays a major role in cell cycle arrest
by inducing the cyclin-dependent kinase inhibitor p21
and the pro-apoptotic factor bax, DN-p63 isoforms
might constitute an alternative mechanism to over-
come p53-mediated cell cycle arrest and apoptosis in
basal cells.1–4,7,15,16 Interestingly, it has been shown
that in normal skin and SCCs, there is preferential
expression of DN-p63 isoforms.5,6,14 Moreover, Ny-
lander and colleagues14 demonstrated that there is an
inverse correlation between expressions of DN-p63a
and p53 in the normal and hyperplastic squamous
epitheliums of the oral mucosa.14 This is in accord-
ance with functional genetic studies,1–3 which demon-
strate that lack of p63 leads to a failure in the main-
tenance of a stem cell population in stratified epi-
thelia, as well as an absence of structures derived from
the epidermal stem cells, such as hair follicles, mam-
mary, salivary and lachrymal glands. In our study, we
also observed preferential p63 expression in epider-
mal basal cells, basal (germinative hair matrix and
external root sheath) cells of hair follicles, sebaceous
glands and in sweat glands.
p53 is the most frequently altered tumor suppressor
gene in human neoplasms.17 Several lines of evidence
support the concept that imbalances in the p53 path-
way are fundamental to tumor development.17
Whereas p53 mutations are highly prevalent in SCCs,
they are not usually observed in BCCs.18 As expres-
sion of DNp63 isoforms seems to be necessary for
maintaining a basal cell population, owing to their
ability to overcome p53-driven cell cycle arrest and
apoptosis1–4 we attempted to evaluate p63 expression
in BCCs. As expected, p63 was strongly and diffusely
expressed in BCCs, as these neoplastic cells maintain
their basal cell morphology. In addition, as the
DNp63 isoforms are those preferentially expressed in
epidermal basal cells5,7 our findings give further sup-
port to the putative role of p63 as an efficient alterna-
tive mechanism to overcome p53-driven tumor sup-
pressing properties in human epidermal basal cells.
In contrast to the BCCs, the SCCs showed variable
expression of p63. As in normal epidermis, the ter-
minally differentiated cells observed in the squamous
pearls lacked p63 expression; conversely, the imma-
ture/anaplastic cells of the SCCs showed strong p63
expression. It should be noted that in the present
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study, p63 expression failed to correlate with the
SCCs degree of differentiation. We may advance two
explanations for this finding: 1) the small number of
SCC herein evaluated was insufficient to demonstrate
a statistically significant association between these two
parameters; or, 2) based on a previously reported gen-
etic analysis of SCCs,19–21 one of the most frequently
amplified loci in SCCs of the skin is 3q27–28, which
is the locus of p63.19–21 Interestingly, 3q amplification
is the earliest event in SCC tumorigenesis and seems
not to be associated with tumor grade.21 Moreover,
according to studies by Hibi et al.19 and Yamaguchi
et al.,20 the p63 gene is frequently amplified in
squamous cell carcinomas of the head and neck and
lung.19,20 Furthermore, p63 mRNA and protein ex-
pression has been described in SCCs of the cervix,
lung, head and neck and skin.5,8,13,14,19,21 Based on
these findings, the balance of probabilities favors that
p63 overexpression may play a role in the oncogenesis
of SCCs, but it is probably not associated with their
degree of differentiation and with other features as-
sociated with aggressive biological behavior.
A putative application of p63 in routine dermato-
pathology practice makes distinct isSCC from its
mimics. In the present study, all seven cases of isSCC
associated with invasive SCC showed diffuse expres-
sion of p63 in all cell layers. At variance, p63 expres-
sion was restricted to the basal and suprabasal layers
in the normal epidermis and reactive epidermis ad-
jacent to the foci of the ulceration. In contrast to our
findings, Noszczyk & Majewski22 reported that p63 is
also expressed in the basal and prickle layers of the
epidermis during wound healing.22 However, system-
atic studies evaluating p63 expression in putative pre-
neoplastic epidermal lesions, such as actinic keratosis,
Bowen’s disease and bowenoid lesions, as well as in
their mimics, must be carried out to definitively cla-
rify the putative role of p63 expression in the differen-
tial diagnosis of these lesions.
In conclusion, we herein evaluated expression of
p63 in normal skin, including cutaneous appendages,
as well as in usual skin carcinomas. p63 is consistently
expressed in epidermal and adnexal basal cells. More-
over, our findings warrant that further studies evalu-
ating differential expression of p63 isoforms in BCCs
and SCC must be carried out in order to clarify the
role of the different p63 isoforms in the oncogenesis
and differentiation of cutaneous carcinomas.
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